lect 1 Flashcards

1
Q

drugs

A

chem substance for tratment/diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

biologic drugs

A

vaccine, protein, antibody (living things)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

small molecule drugs

A

manufactured w/ chem syn and living things (aspirin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ethical pharmaceutical company

A

discover molecular entities (large companies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

generic pharm. company

A

adapt/break patent
manuf and formulate methods
product is not protected from patents
go through ABBREVIATED NEW DRUG APPPLICATION–FDA for a new drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

biotech company

A

turn idea–> product
research intensive
less employees
sell fewer products
exist shortly
bought by bigger companies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

contract research company

A

specialty services (biotesting, chem syn)
manuf. research, clinical trials

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

molecular entity

A

pure ingredient–ACTIVE INGREDIENT–acetaminophen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

product

A

ingredients added to molecular entity
DIFF DOSES&FORMULATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

5 steps in making a drug

A

DDCFM
discovery
development
clinical trials
FDA APPROVAL
market

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

discovery
1-3 YRS

A

IDEA, DISCOVER NEW ME
DRUG CANDIDATE PRODUCED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Project initiation

A

disease markable
must make $ back

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

market analysis

A

customers
affordability
current treatment–cost, efficacy, safety, drug liek

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

competitive assessment then research analysis

A

other companies are..?
1st 3 drugs make most $
existing therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

feasible study

A

disease solvable
existing drugs
patent issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

biochem studies

A

proof drug works
animal models

17
Q

medicinal chem

A

identify active molecules
specificity
enter body

18
Q

lead identification

A

HTPS–random screening, tested with same dose, gain yes/no hits, good 500 hits, >hits fake b/c impurity and interference
retest hits using purified samples and ensure specificity
confirmation of structure–spectoscopy, no chiral centres

19
Q

rational drug test

A

design lead using chem structure
start w/sum known to make unknown

20
Q

natural products

A

chem isolated from plants
secondary metabolites (poison)
hard to do SARS
academic labs
penicilin sp3 chiral
scarce

21
Q

combinational chem

A

test compounds in mixture
identify molecules that have desire properties

22
Q

de novo design

A

computer design
3d bio structure

23
Q

lead optimization
DRUG CANDIDATE

A

SARS
parts of molecule interact w/bio target
molecules that enter body

24
Q

Development
1-2 YRS

A

TURN DRUG CANDIDATE INTO A SELLABLE PRODUCT

25
documentation
mistakes sued FDA data patent--novelty, utility, non-obvious
26
safety-->confirm activity
in vitro (glass)--no carcinogens in vivo (living syn)--small animal (primate and other specie) Sulfanilamide—no testing on animal Thalidomide—didn’t use right species before giving to children
27
manufacture
large scale syn (heat and purification) syn at lowest cost
28
formulation INVESTIGATIONAL NEW DRUG
form of pill excipient (other ingred in pill) stabilizers preservatives fillers disintergrants binders flavour/colour/lubricants
29
clinical trials 1-5 YRS
Nuremberg trials--voluntary, consent, animal studies, benefits > risk phase 1--< 100 HEALTHY ppl, range & safety testing, 30% IND fail phase 2 --200-300 ppl, PATIENTS efficacy, 70% IND fail phase 3--1000s ppl PATIENTS, safety, efficacy, 70% fail NEW DRUG APPLICATION
30
market
100 tonnes/year safety testing rare side effects orphan drugs (pharm agent rare condition, >ME's, short clinical trials, tax cred, gradually popular
31
FDA APPROVAL 6MTHS-1.5 YEARS
REMOVAL DATA FROM CT TO ENSURE TESTING DONE PROPERLY DATA SHOWS BENEFIT > RISK
32
DC IND NDA ANDA
1. potential drug. secret structure 2. permission to begin CT (animal trials prior), plan CT 3. permission to enter market (efficacy, safety, dosing, drug labelling) permission to market generic drug (drug identity, dose formulation, administration)
33
FDA & HEALTH CANADA
Safety testing done by companies full data sent to FDA Approval to market inspection manufacture report difficulties